UPDATE 1-U.S. to boost monkeypox vaccine supply, adding 1.8 million doses

Reuters2022-08-18

(Adds case numbers and quote)

By Ahmed Aboulenein and Kanishka Singh

WASHINGTON, Aug 18 (Reuters) - The United States will boost its supply of monkeypox vaccine by making an additional 1.8 million doses of Bavarian Nordic's Jynneos vaccine available for ordering starting Aug. 22, the White House said on Thursday.

The U.S. Department of Health and Human Services $(HHS)$ will make 360,000 vials of the vaccine available, Assistant Secretary for Preparedness and Response Dawn O'Connell said in a White House briefing. This is the equivalent of 1.8 million doses as the Food and Drug Administration (FDA) last week authorized administering the shot intradermally or between the layers of the skin, increasing by fivefold the doses that can be used from a vial.

The number of cases in the United States has been growing, with over 13,500 reported as of Aug. 17, U.S. Centers for Disease Control and Prevention Director $(CDC)$ Rochelle Walensky said at the briefing. This represents more than a third of the global total of 39,000 cases.

The health department is setting aside 50,000 doses of vaccine from the Strategic National Stockpile that health departments in places hosting large events that attract at-risk groups can request to order on top of their existing allocations and supply, said Bob Fenton, White House monkeypox response coordinator.

The department is also making 50,000 courses of SIGA Technologies Inc's TPOXX antiviral treatment available for people who test positive, which state and local health departments can start ordering starting next week, Fenton said.

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ GRAPHIC - Tracking global monkeypox cases

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

(Reporting by Ahmed Aboulenein and Kanishka Singh; Editing by Mark Porter and Frances Kerry)

((ahmed.aboulenein@tr.com; +1 202-519-3051;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment